‘NRG-HN002: A Randomized Phase II Trial for Patients with p16 Positive, Non-Smoking Associated, Locoregionally Advanced Oropharyngeal Cancer, NCT02254278’ of page ‘NRG-HN002’
View NRG-HN002 PowerPoint Presentation Principal Investigator/Radiation Oncology Sue S. Yom, MD, PhD Primary Objective To select the arm(s) achieving a 2-year progression-free survival rate of ≥ 85% without unacceptable swallowing toxicity at 1 year Patient Population Pathologically (histologically or cytologically) proven diagnosis of squamous cell carcinoma (including the histological variants papillary squamous cell carcinoma and […]
Read More